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Abstract
Purpose: The increasing incidence of small renal tumors in an aging population with comorbidities has stimulated the
development of minimally invasive treatments. This study aimed to assess the efficacy and demonstrate feasibility of
multimodality imaging of intratumoral administration of holmium-166 microspheres (166HoAcAcMS). This new technique
locally ablates renal tumors through high-energy beta particles, while the gamma rays allow for nuclear imaging and the
paramagnetism of holmium allows for MRI.
Methods: 166HoAcAcMS were administered intratumorally in orthotopic renal tumors (Balb/C mice). Post administration CT,
SPECT and MRI was performed. At several time points (2 h, 1, 2, 3, 7 and 14 days) after MS administration, tumors were
measured and histologically analyzed. Holmium accumulation in organs was measured using inductively coupled plasma
mass spectrometry.
Results: 166HoAcAcMS were successfully administered to tumor bearing mice. A striking near-complete tumor-control was
observed in 166HoAcAcMS treated mice (0.1060.01 cm3 vs. 4.1560.3 cm3 for control tumors). Focal necrosis and
inflammation was present from 24 h following treatment. Renal parenchyma outside the radiated region showed no
histological alterations. Post administration CT, MRI and SPECT imaging revealed clear deposits of 166HoAcAcMS in the
kidney.
Conclusions: Intratumorally administered 166HoAcAcMS has great potential as a new local treatment of renal tumors for
surgically unfit patients. In addition to strong cancer control, it provides powerful multimodality imaging opportunities.
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Introduction
Kidney cancer accounts for approximately 3% of all cancers.
With a world-wide incidence of 208,000 new cases and a mortality
of 102,000 patients each year, it is one of the most lethal
genitourinary malignancies [1]. In recent years a dramatic
increase of incidentally detected small renal tumors has occurred,
mainly due to more widespread use of non-invasive imaging
techniques. These tumors are frequently found in patients who are
at surgical risk due to factors such as advanced age and
comorbidities [2]. It has been shown that not every patient will
benefit from surgical resection of the tumor and that it is better to
avoid surgically-induced morbidity in several cases [3,4,5]. The
recommended treatment for small renal tumors is nephron-sparing
surgery [6], but for patients for whom surgical resection is
considered inappropriate, minimally invasive techniques are also
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being developed [7,8]. Although historically external beam
radiotherapy (EBRT) has not been effective for treatment of renal
tumors due to breathing-related movement of the kidneys and
radiosensitivity of adjacent tissue, new radiation methods may
provide a successful alternative [9]. An important new develop-
ment to circumvent the radiosensitivity issues of healthy tissue
around the tumor is the selective local administration of
radioactive sources to the tumor [10,11]. An example of this
selective local administration is transcatheter radioembolization
with yttrium-90 (90Y) resin and glass microspheres (MS), which has
shown promising results in treatment of unresectable hepatic
metastases [12,13,14]. Possibly, intratumoral injection might be
more effective than intra-arterial injection [15]. In this paper, a
novel local ablation technique is presented using small (10–15 mm)
holmium-166 acetylacetonate microspheres (166HoAcAcMS) with
a high holmium load [16]. 166Ho emits both high-energy beta
particles (Ebmax 1.77 and 1.85 MeV, maximum tissue penetration
8 mm, mean tissue penetration 2.5 mm) and gamma rays (0.081
MeV) that allow for nuclear imaging and has a half-life of 26.8 h
[17]. Moreover, non-radioactive holmium-165 can be visualized
by CT and MRI, due to its high mass attenuation coefficient and
its paramagnetic properties, respectively [18]. These imaging
opportunities offer many advantages such as visualizing the
distribution of holmium microspheres inter- and post-treatment
for direct therapy evaluation and follow-up, as well as MRI-based
absorbed dose estimation [19]. This study provides a proof of
principle for intratumoral administration of 166HoAcAcMS as a
novel treatment strategy for kidney cancer in patients not eligible
for surgery, and demonstrates the elegant in vivo multimodality
imaging necessary for treatment guidance and monitoring.
Materials and Methods
Cell culture
Balb/C renal carcinoma cells (Renca, National Cancer
Institute, USA) were maintained at 37uC and 5% CO2 in
Dulbecco’s Modified Eagle’s Medium (Lonza, the Netherlands)
supplemented with 10% fetal bovine serum (Lonza, the Nether-
lands), 1% penicillin/streptomycin and 1% glutamine. To prepare
for in vivo transplantation, cells were trypsinized, washed and kept
on ice until transplantation.
Ethics Statement
All experimental protocols were conducted in agreement with
the Netherlands Experiments on Animals Act and the European
convention guidelines, and accepted by the Animal Experiments
Committee Utrecht, the Netherlands (2009.III.01.003).
Animal experiments
Male Balb/C mice (Charles River, the Netherlands) aged 9–11
weeks were used for experiments. All surgical procedures were
performed under isoflurane anesthesia (IsoFlo, Abbott Animal
Health, the Netherlands). To provide analgesia each mouse
received 3 mg buprenorfine subcutaneously (Buprecare, AST
Pharma, the Netherlands) prior to, and 24 h post surgery.
Orthotopic kidney tumor model
In 60 mice, the left kidney was exposed through a flank incision
and a Renca tumor cube of 2 mm diameter was transplanted
under the renal capsule. Renal tumors were allowed to grow for 1
week, while well being of mice was followed by measuring body
weight and scoring physical appearance.
Holmium acetylacetonate MS
HoAcAcMS were prepared as described by Bult et al [17]. In
short, HoAcAcMS were prepared using a solvent evaporation
technique. Holmium acetylacetonate was dissolved in chloroform
(HPLC grade, Sigma Aldrich, The Netherlands), followed by
emulsification in water containing 2% polyvinylalcohol (average
MW 30,000–70,000 Da, Sigma Aldrich, The Netherlands) as an
emulsifier. After evaporation of chloroform under continuous
stirring, HoAcAcMS were harvested and washed with water
before sieving to obtain the preferred particle size (10–15 um).
The sieve fractions were dried at 40uC. The particle size was
determined using a Coulter Counter, and the holmium content
was determined using the complexometric titration as described by
Zielhuis et al. [20]. Sixty mg HoAcAcMS was transferred to a
high-density poly-ethylene vial (Posthumus Plastics, the Nether-
lands), and neutron irradiated for one hour with a thermal neutron
flux of 561012 n cm22 s21, using the pneumatic rabbit system in a
nuclear reactor (Reactor Institute Delft, the Netherlands) to render
the MS radioactive. Radionuclidic purity was determined batch-
wise after neutron activation to 166HoAcAcMS. Analysis was done
by gamma spectroscopy using a high-purity germanium detector
and GammaVision software. The gamma spectrum obtained was
compared to reference data for holmium-166 from ICRP 38
(ICRP, 1983. Radionuclide Transformations – Energy and
Intensity of Emissions. ICRP Publication 38. Ann. ICRP 11–13).
For the batch of 165HoAcAcMS used in this study no peaks other
than from holmium-166 were detectable after neutron activation.
To assess the MS integrity after neutron irradiation particle size
was determined using a coulter counter (Multisizer 3, Beckman
Coulter, the Netherlands), performing light microscopy and
electron microscopy (Phenom, Phenom B.V., the Netherlands).
The size of the HoAcAcMS used range from 10–15 mm. Earlier in
vitro and in vivo stability studies conducted with these HoAcAcMS
before and after neutron irradiation have been described in detail
by Bult et al. [21]. Briefly, in vitro release of holmium was assessed
after incubation at 37uC in phosphate buffer for 24 hours up to
180 days showing ,0.3% and ,0.5% free holmium, respectively.
HoAcAcMS before and after neutron irradiation were also
administered intratumorally in VX2 tumor-bearing rabbits. No
holmium was detected in the faeces, urine, femur and blood of the
rabbits, and histological examination of the tumor revealed
clusters of intact microspheres amidst necrotic tissue after thirty
days. These studies have shown that the radiochemical purity and
stability of the HoAcAcMS is high and diffusion throughout the
tissue is not expected.
Administration of microspheres
Radioactive 166HoAcAcMS (600 MBq) were suspended in
1.2 ml of an aqueous poloxamer F68 solution (PluronicH solution,
2% w/v), and 50 ml was taken up in 29 G insulin syringes (Becton
Dickinson Ultra Fine, the Netherlands). The activity was measured
using a dose calibrator (VDC-404, Veenstra Instruments, the
Netherlands). Prior to administration, the syringes were placed in
an acrylic glass cylinder to limit the dose to the hands. The syringe
was agitated vigorously to obtain a homogenous suspension and
10 ml of the 166HoAcAcMS (approximately 5 MBq or 500 mg MS)
suspension was administered intratumorally via an open surgical
approach (n= 4–5/group). After administration the syringes were
measured in a dose calibrator to calculate the dose administered to
the tumors. Control mice (n = 3–7/group) received intratumoral
administration of 0.9% NaCl. At 2 hours, 1, 2, 3, 7 and 14 days
after administration of MS mice were sacrificed by cervical
dislocation.
Radioactive Microspheres as Renal Cancer Treatment
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Imaging
Immediately following administration of 166HoAcAcMS, anes-
thetized mice were placed in a small animal CT (U-CT, MILabs,
the Netherlands). Images were acquired at a tube voltage of
45 kV, a tube current of 350 mAs and a voxel size of 83 mm
(isotropic). Two mice underwent multimodality imaging. Single
Photon Emission Computed Tomography imaging (SPECT) was
performed on a U-SPECT system (MILabs, the Netherlands) with
a general purpose mouse collimator (75 focussing 0.6 mm
diameter pinholes) to assess the 166HoAcAcMS distribution on a
sub-half-millimeter resolution [22]. Images were reconstructed
using previously described methods [23], and compensated for
distance dependent sensitivity and blurring of the projection of the
pinholes during reconstruction through point source based system
calibration [24]. The images were registered using an automated
registration programme, using set reference points/bed positions.
From the SPECT images, the dose distribution could be calculated
as described by the MIRD S-voxel method [25]. The MCNPX
2.5.0 Monte Carlo Code [26] was used to estimate the 166Ho dose
convolution kernel. For each voxel in a 15.375 mm3 cube of tissue
material (r=1.06 g cm21) the absorbed dose was calculated as a
result of the 166Ho source uniformly distributed in the center voxel
of the cube. The voxel size chosen was 375 mm (isotropic), equal to
the voxel size of the reconstructed SPECT images. Dose maps
were calculated by convolution of the SPECT images with a
simulated 166Ho dose kernel. MRI was performed on a 4.7 T
horizontal bore small animal scanner (Agilent, UK). Images were
acquired using a multi-slice gradient echo MR sequence with an
echo time of 3.0 msec and repetition time of 242 msec, a field of
view (FOV) of 64632 mm2, a scan matrix of 2566128 with 38
slices resulting in a voxel size of 0.2560.2560.5 mm3, eight signal
averages and a 25u flip angle.
Histopathologic analysis
Tumor-bearing and contralateral kidney, liver, spleen and
heart/lung were weighed and radioactivity was measured in a dose
calibrator for qualitative purposes. Quantification of holmium was
performed by inductively coupled plasma mass spectrometry.
Tumor size was measured using digital callipers and tumor
volumes were calculated using the equation V= (A60.5)6B2
(A= largest diameter, B= smallest diameter). Tumor-bearing
kidneys were processed and embedded in paraffin. A haematox-
ylin and eosin (HE) section of each kidney was evaluated for
glomerular, tubular and vascular changes and inflammation of the
irradiated tumor and surrounding renal parenchyma, as previously
described [27,28].
Inductively coupled plasma mass spectrometry
Inductively coupled plasma mass spectrometry (ICP MS) was
performed to determine the holmium content in the organs used
for histopathologic analysis after NaCl or 166HoAcAcMS treat-
ment. Paraffin was removed from embedded tissue by gentle
heating. The organs were digested in 1 mL aqua regia (concentrated
nitric, perchloric, and sulphuric acid in a ratio 4:1:1) under
heating. After destruction, all samples were passed through cotton
gauze to remove the insoluble paraffin residue. The samples were
diluted in 2% nitric acid, and measured on a Varian 820 MS
(Varian, the Netherlands), with a detection limit of 0.1 nanogram
holmium mL21 using standard holmium reference material
(CertiPUR Holmium ICP Standard (traceable to SRM from
NIST), Merck, Darmstadt, Germany).
Results
Microsphere administration
MS had a smooth surface, both before and after neutron
irradiation and holmium content of the MS was 45% (w/w). The
size distribution was not affected by neutron irradiation, and the
specific activity of the 166HoAcAcMS was 10 MBq mg21 corre-
sponding with 22 Bq ng21 holmium at the time of delivery.
166HoAcAcMS were successfully administered to 24 Renca tumor-
bearing Balb/C mice. As a control, 36 (n = 3–7 mice per time
point) tumor-bearing animals received 10 ml of saline. The mean
tumor diameter at the time of treatment was 5.6 mm61.6 mm.
The average administered dose was 2.7 MBq61.2 MBq (corre-
sponding to 2706120 mg 166HoAcAcMS). Hence the detection
limit expressed as percentage of the injected dose of holmium was
0.961024%.
Efficacy
Neither discomfort nor aberrant behaviour was observed in
these mice. The bodyweight of mice in the 166HoAcAcMS
(22.261.8 g) and saline group (22.161.2 g) remained constant
throughout the experiment. The efficacy of 166HoAcAcMS after
intratumoral injection is depicted in Figure 1A. The tumor volume
in the saline control group increased from 0.1260.03 cm3 (day 3
after treatment) to 4.1560.3 cm3 two weeks post injection.
Importantly, the tumor volume in the 166HoAcAcMS group
remained constant from 0.1460.01 cm3 at three days post
injection to 0.1060.01 cm3 after two weeks. ICP MS analysis
showed that 72.9% (33.1–83.6) (median (IQR)) of the total
holmium measured was detected in the tumors of mice that
received 166HoAcAcMS. In 15 mice in the holmium group 16.9%
(IQR 2.6–52.5) holmium was found in the lungs, most likely due to
the inadvertent delivery of 166HoAcAcMS in a blood vessel in or
around the tumor [14].
Histology
166HoAcAcMS were present as focal intratumoral deposits
(Figure 1D). Tumor necrosis was visible at the site of injection
from 24 h following 166HoAcAcMS administration (Figure 1D),
inflammatory cells were visible within 48 h (Figure 1E). Grade 3
radiation damage [27] was only visible in renal parenchyma
directly surrounding the tumor 2 weeks after treatment (Figure 1F).
In all cases, renal parenchyma outside the radiated region showed
no glomerular, tubular or vascular alterations (Figure 1A).
Imaging
The powerful multimodality imaging characteristics of holmium
were demonstrated with CT, SPECT and MRI in mice that were
terminated immediately following intratumoral administration of
166HoAcAcMS (Figure 2A to D). CT imaging revealed deposits of
166HoAcAcMS (approximately 300 mg, corresponding to 2.7 MBq
166Ho) in the kidney area. Substantial accumulation of particles
was seen at the site of injection (Figure 2B). 166HoAcAcMS were
clearly visualized using SPECT imaging and the SPECT images
served as a template for the construction of a dose map (Figure 2E).
The dose map shows a selective deposition of therapeutic beta
particles at the site of injection, leading to a local tumor absorbed
dose in excess of 2200 Gy. The average tumor dose was calculated
using the equation as postulated by Vente et al.: Dose
(Gy) = (Dosage administered (MBq) 615.87 mJ MBq21)/tumor
weight (g) [29]. The calculated average tumor dose in this study
was 323 Gy. The radiation dose to the healthy tissue was below
23 Gy in the largest part of the kidney and surrounding organs
(Figure 2F). For a more detailed anatomical depiction of the soft
Radioactive Microspheres as Renal Cancer Treatment
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tissue, MR images were acquired. On T2* weighted MRI scans,
holmium causes a rapid signal decay due to the paramagnetic
nature of this element. Consequently, holmium appears as
blackening on T2* weighted images. As can be seen in Figure 3,
holmium is clearly visible as a dark spot in the upper side of the
kidney, where it was administered in the tumor. By combining the
sensitivity and high quantitative accuracy of SPECT imaging
[30,31,32] with the soft tissue imaging of MRI, the 166HoAcAcMS
therapy can accurately be evaluated to ensure complete tumor
ablation.
Discussion
The feasibility and efficacy of 166HoAcAcMS as a minimally
invasive treatment was assessed in a mouse model for kidney
cancer. Importantly, the intratumoral administration of 2.7 MBq
166HoAcAcMS arrested tumor growth, which was apparent one
week post-administration when approximately 95% of the ionizing
radiation dose has been delivered. Assuming all beta energy is
deposited in the tumor, the calculated average tumor absorbed
dose was 323 Gy, with local doses as high as 2200 Gy. The
average tumor absorbed dose is approximately 4–5 fold higher
than the 60–80 Gy absorbed dose used in EBRT as a value
sufficient for complete tumor kill. Despite the high calculated
absorbed dose, the localized nature of the radiation dose
considerably reduces unwanted damage of surrounding tissues.
The radiation dose to the healthy tissue was below 23 Gy in the
largest part of the kidney and surrounding organs. 23 Gy is the
maximum tolerance dose for uniform kidney irradiation [33].
Given the maximum penetration depth of the emitted beta
particles (8 mm) and the larger size of the kidney, the radiation
dose to healthy parenchyma is expected to be negligible when
translating to the clinical situation.
In addition to efficacy, the feasibility of multimodality imaging
of 166HoAcAcMS was demonstrated. Deposits of approximately
2.7 MBq or 270 micrograms of 166HoAcAcMS were clearly visible
on SPECT, or CT and MRI. 166HoAcAcMS can therefore be
regarded as a true multimodality imaging agent. The specificity of
SPECT was superior to that of both CT and MRI. In this study
CT imaging was used to determine the distribution of 166HoA-
cAcMS, since the low amounts of activity administered result in a
long acquisition time with SPECT (6 minutes for CT versus
45 minutes SPECT). However, in patients faster SPECT image
acquisition will be possible, as the amount of activity will be 20- to
100-fold higher. Furthermore, by combining the sensitivity and
high quantitative accuracy of SPECT imaging [30,31,32] with the
soft tissue imaging of MRI, the 166HoAcAcMS therapy could
accurately be evaluated to ensure complete tumor ablation during
the procedure.
The use of radioactive microspheres in the treatment of an
experimental tumor model was successful, and results are very
promising. Although the orthotopic mouse model resembles the
human situation in many aspects, a number of points need to be
addressed before intratumoral administration of 166HoAcAcMS
could be routinely applied in humans. First of all, toxicity studies
should be performed in humans. The in vivo stability of the
HoAcAcMS was assessed in a tumor bearing rabbit model, which
showed the stability of the HoAcAcMS for up to one month, and
no toxicity was observed [21]. Radioactive holmium poly(L-lactic
acid) particles of 20–50 mm for intra-arterial application have been
evaluated for biodistribution, efficacy and toxicity in rats, rabbits
and pigs, and have shown their stability and safety [29,34], a
phase-I study of patients with liver metastases has recently been
performed [35,36]. Similar toxicity experiments will need to be
performed for the 166HoAcAcMS described here prior to initiating
a clinical trial.
Tumors in study ranged from 4 to 8 mm at the time of
treatment, which is similar to the penetration range of the beta
particles in tissue. It is expected that for nephron-sparing
treatment of tumors smaller than 4 cm, 4 to 8 injections with
166HoAcAcMS are required for an effective eradication. This is
comparable to conventional minimally invasive ablative treat-
ments that often need multiple probes to achieve complete tumor
kill [37]. The advantage of radionuclide therapy compared to
thermal ablative minimally invasive techniques is the prolonged
delivery of energy to the tumor tissue, due to the half life. Using
multiple deposits of 166HoAcAcMS, an accurate delivery of the
dose can be given independent of shape and size of the tumor. As
observed, an average tumor dose of 323 Gy was obtained with one
deposit. When positioning the deposits within 1 cm apart it is
Figure 1. Intratumoral injection of 166HoAcAcMS is an effec-
tive, minimally invasive procedure in kindney cancer. (A) Tumor
volume at different time points after treatment. The solid line
represents the tumor volume of the 166HoAcAcMS group. The dashed
line represents the tumor volume of the saline control group. (B) HE
staining of kidney and tumor tissue 2 weeks after 166HoAcAcMS
treatment (n indicates normal kidney, t indicates tumor.) (C) HE staining
(206) of renal parenchyma outside the radiated region 2 weeks
following 166HoAcAcMS administration, showing no glomerular, tubular
or vascular alterations. (D) HE staining (206) of irradiated tumor 1 day
following 166HoAcAcMS administration. HoAcAcMS are present as focal
intratumoral deposits (arrows). At the site of injection, tumor necrosis
and cell death is visible. (E) HE staining of irradiated tumor (206) 2 days
following 166HoAcAcMS administration. Inflammatory cells are present
at the radiated area. (F) HE staining of irradiated tumor (206) 1 week
after 166HoAcAcMS administration. Grade 3 radiation damage [27] is
only visible in renal parenchyma directly surrounding the tumor.
doi:10.1371/journal.pone.0052178.g001
Radioactive Microspheres as Renal Cancer Treatment
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expected that complete tumor kill can be achieved. However,
more research is warranted to further investigate the relationship
between deposit localisation and tumor kill in larger tumors.
A technical problem we encountered was the delivery of
approximately 50% of the intended dose (5 MBq), possibly due to
adsorption of radioactive MS onto the syringe wall and dosage
errors due to the small injected volume. When treating patients,
the administered volume is higher, resulting in a smaller difference
between aimed and actual administered dose. Furthermore,
varying concentrations of holmium were found in the lungs of
several mice. Tumor vascularity as well as particle size is an
important factor for the fate of the radioactivity [38]. Although the
presence of holmium in the lungs is likely due to the inadvertent
vascular delivery of the MS during the intratumoral injections [14]
and with a size of 12.5 mm diffusion within the tissue is less likely, a
future study should be performed to examine these two factors
specifically. Lung uptake was not observed when administering
166HoAcAcMS percutaneously under ultrasound guidance in
Figure 2. An example of the multimodality imaging characteristics of intratumorally administered 166HoAcAcMS. Images are acquired
immediately following administration of the MS. (A) A schematic representation of the mouse anatomy (I: Lungs; II: Liver; III: Stomach; IV: Kidney; *:
Artefact caused by holmium on MRI image 3C) (B) CT image, depicting the HoAcAcMS in the kidney area as a white area (arrow). (C) MR image
showing the soft tissue detail of this imaging modality and the deposition of HoAcAcMS as a dark spot. (D) SPECT image, showing a selective
visualisation of radioactive MS in the kidney area. (E) Fused SPECT and CT image. (F) MRI image fused with the dose map, showing the absorbed dose
distribution in the kidney area.
doi:10.1371/journal.pone.0052178.g002
Figure 3. Schematic drawing showing the percutaneous ap-
proach to 166HoAcAcMS administration. The patient is placed in
lateral position in an angiography suite. The 166HoAcAcMS are adminis-
tered intratumorally by a shielded syringe under real-time CT guidance.
doi:10.1371/journal.pone.0052178.g003
Radioactive Microspheres as Renal Cancer Treatment
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hypervascular feline liver tumors [38]. Ultrasound guidance not
only helps to distinguish healthy tissue from tumorous tissue, it also
visualises tumor vasculature. Unfortunately, percutaneous ultra-
sound guided administration was not feasible in this model.
Nevertheless, in patients the procedure should be performed
percutaneously under CT or ultrasound guidance, to ensure
accurate delivery and avoid inadvertent vascular delivery. An
illustration of a CT guided approach is shown in Figure 3. A new
method that could be used is the multiplanar Global Positioning
System-like technology [39]. A minimally invasive approach
would make intratumoral administration of 166HoAcAcMS
suitable for treatment of patients for whom surgical resection is
considered inappropriate.
Conclusions
The present study demonstrates that intratumoral administra-
tion of 166HoAcAcMS is a promising novel minimally invasive
treatment of kidney cancer. Tumor growth was arrested and no
signs of radiation damage outside the treatment zone were
observed. Importantly, multimodality imaging including CT,
SPECT and MRI of small amounts of 166HoAcAcMS was
feasible. This will lead to an improved therapy evaluation and
follow-up and provides a fundamental advantage over current
therapies.
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